What is the best medication for a 67-year-old experiencing hot flashes?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Best Medication for Hot Flashes in a 67-Year-Old

Fezolinetant is the recommended first-line non-hormonal treatment for moderate to severe hot flashes in a 67-year-old woman, offering targeted action on hot flash pathophysiology with fewer side effects than alternatives. 1

First-Line Treatment Options

  • Fezolinetant is recommended as first-line non-hormonal therapy for hot flashes, with significant improvements typically seen by week 4 1
  • Fezolinetant avoids the 10-20% treatment withdrawal rate seen with SSRIs/SNRIs and doesn't require gradual discontinuation to prevent withdrawal symptoms 1
  • Fezolinetant has a more targeted mechanism of action specific to hot flash pathophysiology and doesn't have potential drug interactions with tamoxifen through CYP2D6 inhibition 1

Alternative Medication Options

SSRIs/SNRIs

  • Venlafaxine (37.5-75 mg daily) reduces hot flashes by approximately 60%, with significant declines in both frequency and severity compared to placebo 2, 3
  • Paroxetine (10-20 mg daily) demonstrates 40-65% reduction in hot flash frequency and composite scores, with low-dose options (7.5-12.5 mg/day) showing improved tolerability 2, 4
  • For women taking tamoxifen, avoid paroxetine and fluoxetine as they may decrease plasma levels of endoxifen (active tamoxifen metabolite) through CYP2D6 inhibition 2
  • Citalopram and venlafaxine have minimal effects on tamoxifen metabolism and are better alternatives for breast cancer patients on tamoxifen 2

Gabapentin

  • Gabapentin (900 mg/day) reduces hot flashes by 46-49% at 8 weeks compared to 15-21% with placebo 2
  • Gabapentin has no known drug interactions and no absolute contraindications, making it suitable for women with complex medication regimens 2
  • Side effects include somnolence, fatigue, dizziness, and unsteadiness, but these typically improve after the first week of treatment 2
  • Gabapentin is the only non-hormonal treatment demonstrated to have equivalent efficacy to estrogen in treating hot flashes 2

Other Options

  • Clonidine (oral or transdermal) shows modest efficacy but has limited utility due to side effects 3, 5
  • Hormone therapy remains the most effective treatment for hot flashes (80-90% reduction) but carries risks including increased stroke and breast cancer risk 1, 6

Treatment Algorithm for Hot Flashes at Age 67

  1. Assess severity and impact: If hot flashes are mild and don't interfere with sleep or daily function, consider non-pharmacological approaches with vitamin E (800 IU/day) 3

  2. For moderate to severe symptoms:

    • First choice: Fezolinetant (if available) 1
    • Second choice (if fezolinetant unavailable or contraindicated):
      • For women without breast cancer history: Venlafaxine starting at 37.5 mg daily, increasing to 75 mg after 1 week if needed 2
      • For women with breast cancer on tamoxifen: Venlafaxine or citalopram (avoid paroxetine/fluoxetine) 2
      • Alternative: Gabapentin 900 mg/day (particularly if SSRIs/SNRIs are contraindicated) 2
  3. If initial therapy fails: Switch to an alternative medication class (e.g., from SSRI/SNRI to gabapentin or vice versa) 2, 7

Important Considerations

  • Most medications show significant placebo effect (13-29%) in hot flash treatment, suggesting some women may benefit from a limited trial 2
  • Hot flashes may decrease over time naturally, even in women receiving treatment 2
  • Non-pharmacologic adjuncts like cognitive behavioral therapy, weight loss if overweight, smoking cessation, and acupuncture can help reduce hot flash symptoms 1

References

Guideline

Fezolinetant for Treating Hot Flashes in Menopausal Women

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Pathophysiology and treatment of hot flashes.

Mayo Clinic proceedings, 2002

Research

Critical appraisal of paroxetine for the treatment of vasomotor symptoms.

International journal of women's health, 2015

Research

Treatment options for menopausal hot flashes.

Cleveland Clinic journal of medicine, 2004

Research

Centrally active nonhormonal hot flash therapies.

The American journal of medicine, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.